Psychedelics
September 8, 2026
Hongyuan Li, Xiaohui Wang
Central nervous system (CNS) injuries remain challenging to treat due to limited neurogenesis, inhibitory extracellular environments, and maladaptive neuroimmune responses. Psychedelic compounds, including classical serotonergic psychedelics, dissociative anesthetics, and empathogens, have re-emerged as mechanistically distinctive “psychoplastogens” capable of rapidly and persistently enhancing...
Zenodo (CERN European Organization for Nuclear Research)
September 7, 2026
Christian Alexander Brown
preprint
This research essay/article argues that cannabis can reasonably be described as psychedelic in a phenomenological sense, even though it is not pharmacologically classified as a classic serotonergic psychedelic such as LSD or psilocybin. The central distinction is between pharmacology and phenomenology: THC acts primarily through the endocannabinoid system, especially CB1 receptor signaling, yet...
Brain Research
September 7, 2026
Eleni Kroupi, Helena Araujo, Cas Oosterveld et al.
N,N-Dimethyltryptamine (DMT), a potent serotonin-2A receptor agonist, elicits intense psychedelic experiences and has become a focus of interest in neuroscience and mental health research. While EEG studies of psychedelics typically report reduced alpha power, increased delta power, and enhanced signal complexity-primarily assessed using Lempel-Ziv complexity (LZc)-less is known about DMT's...
Zenodo (CERN European Organization for Nuclear Research)
September 7, 2026
Flávio Marco Rego da Silva
preprint
Rationale: Increased neural complexity under psychedelics is replicated, but the temporal structure carrying it — and the design choices that decide what a "complexity increase" means — remain contested: window-level reports treat correlated windows as independent; cross-dataset contrasts confound pharmacology with protocol. Objectives: To test, in public EEG datasets with pre-registered...
Journal of Psychoactive Drugs
September 7, 2026
Damian Swieczkowski, Aleksander Kwaśny, Wiesław Jerzy Cubała
This qualitative study examines self-reported experiences with 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) shared on Reddit to explore subjective reports, contextual influences, and perceived effects. A total of 120 posts from 24 discussion threads were purposively selected and thematically analyzed using an inductive, constructivist approach. The analysis resulted in 48 codes, which were...
The World Journal of Biological Psychiatry
September 6, 2026
Balwinder Singh, Siamak MahmoudianDehkordi, Jennifer L. Vande Voort et al.
OBJECTIVE: Ketamine is a rapid-acting antidepressant with an incompletely understood mechanism of action. Pharmacometabolomics can identify pathways underlying its effects and response variability. Using data from the Bio-K trial (NCT03156504), a multisite open-label study, we characterised metabolomic signatures of intravenous (IV) racemic ketamine in adults with treatment-resistant depression...
Journal of Psychopharmacology
September 3, 2026
Katelijne V. van der Heijden, Gabriël E. Jacobs, Ellen James et al.
Serotonergic psychedelics, such as N,N-dimethyltryptamine (DMT), have shown therapeutic potential in various psychiatric disorders. However, DMT demonstrates pharmacokinetic (PK) variability and a short half-life. This exploratory study investigated the PK, pharmacodynamic (PD), and safety profile of CYB004, a deuterated DMT analogue, following intravenous administration in healthy volunteers....
Biological Psychiatry Global Open Science
September 1, 2026
Elizabeth A Virakorn, Kathryn Baker, Nicholas A. Everett et al.
Background Recent work suggests that psilocybin, a hallucinogenic 5-HT 2A R agonist with rapid and long-lasting anti-depressant actions, facilitates fear extinction retention in adult rodents. However, psilocybin’s effects on adolescent fear extinction are unknown. Further, chronic stress in adolescence predisposes individuals to developing psychopathologies such as anxiety and fear-related...
The International Journal of Neuropsychopharmacology
September 1, 2026
W. Cubała, Kelly Doolin, Fiona Ryan et al.
Abstract Background Treatment-resistant depression (TRD) represents a particularly challenging form of major depressive disorder (MDD), defined by an inadequate response to at least two antidepressants given at adequate dose and duration within the current depressive episode. TRD affects nearly one-third of individuals with MDD and is consistently linked to greater psychiatric and medical...
The International Journal of Neuropsychopharmacology
September 1, 2026
Gabriella Gobbi
Abstract Background Lysergic acid diethylamide (LSD), a serotonergic psychedelic, has gained renewed interest for its potential anxiolytic effects in clinical trials. However, the neurobiological mechanisms underlying these effects remain poorly understood. Aims & Objectives The goal of this study is to understand the mechanism of action of LSD in animal models by using in vivo...